文献速递糖尿病肥胖与代谢综合征

肠促胰素治疗的体重下降与心血管结局及死亡率的荟萃回归分析

Association Between Weight Loss on Incretin‐Based Therapy and Cardiovascular Outcomes and Mortality: A Systematic Review and Meta‐Regression
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-11-04

试验水平的安慰剂校正体重降幅与3P-MACE、心血管死亡、全因死亡、心肌梗死、卒中及心力衰竭住院的治疗风险比无显著关联,而荟萃分析显示上述结局均显著下降。

要点

  • 试验水平体重降幅与3P-MACE等心血管结局的治疗HR无显著关联
  • 荟萃分析示3P-MACE降15%、心血管死亡降13%、全因死亡降12%
  • 体重下降对心血管获益的个体水平贡献及因果性尚不能确定

核心结论

  • 试验水平安慰剂校正体重降幅较大与所考察心血管及死亡结局(含3P-MACE与HHF)的较低治疗HR无显著关联。
  • 该结果不排除体重下降在个体水平对心血管获益有贡献,亦未确立因果关系。
  • 需个体参与者水平分析来阐明体重下降与心血管结局的关系。

研究设计与样本

  • 系统综述,检索MEDLINE、EMBASE、CENTRAL和ClinicalTrials.gov的安慰剂对照随机试验。
  • 主要分析为聚合数据荟萃回归,预设调节变量为最近报告随访时间点的安慰剂校正体重百分比差异。
  • 另采用标准荟萃分析估计总体治疗效果。

主要发现

  • 荟萃回归显示较大体重下降与3P-MACE、心血管死亡、全因死亡、心肌梗死、卒中及心力衰竭住院(HHF)的治疗HR无统计学显著关联。
  • 荟萃分析显示3P-MACE显著降低15%。
  • 心血管死亡显著降低13%,全因死亡显著降低12%。
  • 心肌梗死显著降低14%,卒中显著降低13%,HHF显著降低10%。

临床怎么用

  • 解读肠促胰素类药物心血管获益时,不宜仅以试验水平体重降幅推断其心血管保护程度。
  • 药物选择可综合心血管结局证据,体重下降与心血管获益的关系仍需个体水平研究明确。

局限性

  • 为聚合数据荟萃回归,不能确立个体水平或因果关系。
  • 预设调节变量为试验水平安慰剂校正体重差异,非个体体重变化。
  • 原文未报告所纳入试验的具体随访时长及各项异质性指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Aims The primary aim was to evaluate, using aggregate-data meta-regression, whether body weight loss induced by incretin mimetic therapy is associated with reductions in three-point major adverse cardiovascular events (3P-MACE), individual cardiovascular outcomes and mortality. A secondary aim was to estimate the overall cardiovascular effects of incretin mimetics compared with placebo. Methods A systematic review of placebo-controlled randomized trials was conducted using MEDLINE, EMBASE, CENTRAL and ClinicalTrials.gov. Eligible trials reported cardiovascular hazard ratios (HRs) and weight changes. The primary analysis was an aggregate-data meta-regression, with the prespecified moderator defined as the placebo-adjusted percentage weight difference at the latest reported follow-up time point. Standard meta-analysis was performed to estimate overall treatment effects. Results Sixteen randomized trials including 97 199 participants with and without diabetes were analysed. Meta-regression showed no statistically significant association between greater body weight loss and treatment HRs for 3P-MACE, cardiovascular or all-cause mortality, myocardial infarction, stroke and hospitalization for heart failure (HHF). These findings do not establish an individual-level or causal relationship. Meta-analysis showed significant reductions in 3P-MACE (15%), cardiovascular mortality (13%), all-cause mortality (12%), myocardial infarction (14%), stroke (13%) and HHF (10%). Conclusion Greater trial-level placebo-adjusted body weight loss was not significantly associated with lower treatment HRs for the cardiovascular and mortality outcomes examined, including 3P-MACE and HHF. These findings do not exclude an individual-level contribution of weight loss to cardiovascular benefit or establish causality. Individual-participant-level analyses are needed to clarify the relationship between weight loss and cardiovascular outcomes.

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Association Between Weight Loss on Incretin‐Based Therapy and Cardiovascular Outcomes and Mortality: A Systematic Review and Meta‐Regression

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。